World Conference on Lung Cancer(WCLC)

HUDSON: an open-label, multi-drug, biomarker-directed, phase II platform study in patients with NSCLC, who progressed on anti-PD(L)1 therapy [OA07.08]

Immuno-modulatory effects of ceralasertib in combination with durvalumab in NSCLC with progression on anti-PD(L)1 treatment (HUDSON) [P16.07]

Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study [OA03.03]

Interim analysis of neoadjuvant chemoradiotherapy and durvalumab for potentially resectable stage III non-small cell lung cancer (NSCLC) [FP03.02]

Lung cancer symptoms at diagnosis: data from Thoracic Tumors Registry (TTR) [P52.05]

Thoracic Tumors Registry (TTR): Analysis of clinical features and survival in patients with mNSCLC in Spain [P52.08]

Profile of comorbidities and cancer history in patients with mNSCLC in the Spanish population, an interim analysis of the Thoracic Tumors Registry (RTT) [P52.10]

Estimates of first-line extensive stage small cell lung cancer treatment rates from a U.S. claims database [P50.09]

Population pharmacokinetics and exposure-response with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN [P48.21]

Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A [OA01.04]

First-line durvalumab plus platinum-etoposide in ES-SCLC: exploratory analyses based on extent of disease in CASPIAN [P48.03]

An Observational Study of Treatment Outcome in Stage III Lung Cancer Patients in Taiwan: KINDLE study [P21.12]

Real-world treatment patterns in Chinese Stage III NSCLC patients - a prospective, non-interventional study (MOOREA trial) [P21.10]

Durvalumab in locally-advanced NSCLC in LATAM: Real world data from patients included in the early access program [P21.13]

Durvalumab After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study [P17.02]

MERMAID-1: A Phase III study of adjuvant durvalumab plus chemotherapy in resected NSCLC patients with MRD+ post-surgery [P03.03]

Patient characteristics and clinical outcomes of stage III NSCLC in a real-world setting: KINDLE Korean subset data [P04.03]

The monitoring of mutated EGFR levels in liquid biopsy from patients on EGFR-TKIs – early detection of NSCLC progression [P35.05]

Tissue- and plasma-based landscape of resistance to osimertinib [P76.18]

A pan-Canadian validation study for the detection of EGFR-T790M mutations using circulating tumour DNA (ctDNA) from blood [FP07.08]

A phase II study of osimertinib versus combination of osimertinib and chemotherapy for EGFR and T790M-mutation positive NSCLC [FP14.02]

Post hoc analyses from an open label, multi-centre, ASTRIS trial of efficacy of osimertinib for CNS metastases with T790M-positive advanced NSCLC [FP14.14]

A PET and MRI study exploring osimertinib brain exposure and efficacy in EGFRm NSCLC CNS metastases [P76.72]

Osimertinib in poor PS patients with T790M-positive advanced NSCLC after progression of EGFR TKI treatments (NEJ032B) [P76.79]

Osimertinib treatment in non-small cell lung cancer (NSCLC) EGFR-T790M+. Activity in patients with CNS metastases. OSIREX [P76.42]

Real-world, first-line osimertinib treatment in epidermal growth factor receptor mutation-positive (EGFRm) advanced NSCLC [P76.66]

ORCHARD: A biomarker-directed Phase 2 platform study in pts with advanced EGFRm NSCLC progressing on first-line osimertinib [P76.27]

Real-world global data on targeting epidermal growth factor receptor in stage III non-small cell lung cancer: the results of the KINDLE study [P21.12]

Patient-reported outcomes from ADAURA: osimertinib as adjuvant therapy in patients with resected EGFR mutated (EGFRm) NSCLC [OA06.03]

Postoperative chemotherapy patterns and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR mutated NSCLC [OA06.04]

Quantification of BIM mRNA In Circulating Tumor Cells Of Osimertinib-treated Patients with EGFR Mutation-positive Lung Cancer [P34.07]

Retrospective epidemiological study of Locally Advanced Non-Small Cell Lung Cancer patients in Brazil – RELANCE (LACOG 0118) [P18.06]

Phase 1 Study of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib in Patients with Advanced or Metastatic EGFR-Mutated NSCLC [P01.03]

Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy for EGFR mutated resectable NSCLC: NeoADAURA [P03.02]

Alternating osimertinib and gefitinib as second-line treatment for EGFR-mutated NSCLC harbouring a T790M resistance mutation (OSCILLATE) [P76.64]

Osimertinib+savolitinib in pts with EGFRm MET-overexpressed/amplified NSCLC: Phase Ib TATTON Parts B/D final analysis [FP14.03]

Trastuzumab deruxtecan plus pembrolizumab in advanced/metastatic breast or non-small cell lung cancer: A phase 1b study [P01.02]

Trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: interim results of DESTINY-Lung01 [OA04.05]

Trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01 [MA11.03]